Trial NCT05205252

View at ClinicalTrials.gov 
Org. Study IDs: EZH-1501

Last trial update was posted on 2023-08-15

MeSH Interventions

Acalabrutinib Antibodies, Monoclonal Daratumumab Dexamethasone Lenalidomide Pomalidomide Tyrosine Kinase Inhibitors

MeSH Conditions

Hematologic Neoplasms Neoplasms

Other Conditions

Refractory Hematologic Malignancy Relapsed Hematologic Malignancy

Stopping Reasons

Epizyme Inc. has revised the Tazemetostat development strategy and made the decision to terminate the hematological malignancies basket trial.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID